Management of Advanced Stage Hepatocellular Carcinoma with Extensive Portal Vein Tumor Thrombus Using an Adjustable Dual Balloon Occlusion Technique Published in Journal of Vascular and Interventional Radiology, July, 2019

RenovoRx today announced its financial results for the second quarter ended June 30, 2026, and provided shareholders with a business update highlighting continued commercial momentum and clinical progress.

RenovoRx is pleased to announce completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC). 

RenovoRx today announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock (“CARTI”).